{
  "ticker": "PGEN",
  "company_name": "Precigen, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06157151",
      "title": "PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer",
      "start_date": "2025-03-21",
      "completion_date": "2028-01-30",
      "enrollment": 0,
      "sponsor": "Precigen, Inc"
    },
    {
      "nct_id": "NCT06538480",
      "title": "Zopa Retreatment and Vector Shedding in Adults With RRP",
      "status": "RECRUITING",
      "phase": "PHASE4",
      "condition": "Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae",
      "start_date": "2024-07-11",
      "completion_date": "2028-12-02",
      "enrollment": 0,
      "sponsor": "Precigen, Inc"
    },
    {
      "nct_id": "NCT05694364",
      "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies",
      "start_date": "2023-01-25",
      "completion_date": "2024-04-18",
      "enrollment": 0,
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute"
    },
    {
      "nct_id": "NCT03409627",
      "title": "Novel INXN-4001 Triple Effector Plasmid in Heart Failure",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Heart Failure, Cardiovascular Diseases, Heart-Assist Device",
      "start_date": "2018-04-09",
      "completion_date": "2020-08-12",
      "enrollment": 0,
      "sponsor": "Triple-Gene, LLC"
    },
    {
      "nct_id": "NCT04724980",
      "title": "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae",
      "start_date": "2021-03-16",
      "completion_date": "2026-06-05",
      "enrollment": 0,
      "sponsor": "Precigen, Inc"
    },
    {
      "nct_id": "NCT03907527",
      "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8",
      "start_date": "2019-04-30",
      "completion_date": "2028-11-15",
      "enrollment": 0,
      "sponsor": "Precigen, Inc"
    },
    {
      "nct_id": "NCT03927261",
      "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia, Myelodysplastic Syndromes",
      "start_date": "2019-05-20",
      "completion_date": "2025-08-01",
      "enrollment": 0,
      "sponsor": "Precigen, Inc"
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "PHASE2": 1,
      "PHASE4": 1,
      "PHASE1": 4,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 2,
      "COMPLETED": 2,
      "ACTIVE_NOT_RECRUITING": 3
    },
    "active_trials": 5,
    "completed_trials": 2,
    "conditions": [
      "Acute Myeloid Leukemia, Myelodysplastic Syndromes",
      "Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer",
      "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies",
      "Heart Failure, Cardiovascular Diseases, Heart-Assist Device",
      "Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8",
      "Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae",
      "Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:42.131013",
    "search_query": "Precigen, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Precigen,+Inc."
  }
}